GAG
VRTX icon

Goodman Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Goodman Advisory Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-311
Closed -$139K – 173
2026
Q1 		$139K Sell
311
-68
-18% -$31.7K 0.04% 88
2025
Q4 		$172K Hold
379
– – 0.04% 74
2025
Q3 		$148K Sell
379
-21
-5% -$8.78K 0.04% 78
2025
Q2 		$178K Sell
400
-44
-10% -$20.3K 0.06% 59
2025
Q1 		$215K Buy
+444
New +$207K 0.07% 75
2024
Q4 		– Sell
-492
Closed -$229K – 180
2024
Q3 		$229K Hold
492
– – 0.07% 80
2024
Q2 		$231K Sell
492
-7
-1% -$3.04K 0.07% 79
2024
Q1 		$209K Buy
499
+7
+1% +$2.96K 0.07% 69
2023
Q4 		$200K Hold
492
– – 0.07% 67
2023
Q3 		$171K Sell
492
-29
-6% -$10.1K 0.06% 70
2023
Q2 		$183K Hold
521
– – 0.07% 59
2023
Q1 		$164K Sell
521
-274
-34% -$82.2K 0.09% 52
2022
Q4 		$230K Buy
795
+274
+53% +$83.5K 0.13% 43
2022
Q3 		$151K Hold
521
– – 0.08% 53
2022
Q2 		$147K Buy
+521
New +$139K 0.07% 55

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goodman Advisory Group's VRTX Position: Q2 2026 in Review

Goodman Advisory Group sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 311 shares — an estimated $139K sold.

Goodman Advisory Group first reported a position in VRTX in Q2 2022 and held it in 15 quarters. The position peaked at $231K in Q2 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Goodman Advisory Group reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Goodman Advisory Group sold 311 Vertex Pharmaceuticals shares in Q2 2026, an estimated $139K.
  • Goodman Advisory Group first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 15 quarters.
  • Goodman Advisory Group's Vertex Pharmaceuticals position peaked at $231K in Q2 2024.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Goodman Advisory Group's 13F filing for Q2 2026, filed 12 Aug 2026.